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Background: Recent studies have found high prevalences of asymptomatic rectal chlamydia among HIV-infected
men who have sex with men (MSM). Chlamydia could increase the infectivity of HIV and the susceptibility to HIV
infection. We investigate the role of chlamydia in the spread of HIV among MSM and the possible impact of routine
chlamydia screening among HIV-infected MSM at HIV treatment centres on the incidence of chlamydia and HIV in
the overall MSM population.
Methods: A mathematical model was developed to describe the transmission of HIV and chlamydia among MSM.
Parameters relating to sexual behaviour were estimated from data from the Amsterdam Cohort Study among MSM.
Uncertainty analysis was carried out for model parameters without confident estimates. The effects of different
screening strategies for chlamydia were investigated.
Results: Among all new HIV infections in MSM, 15% can be attributed to chlamydia infection. Introduction of
routine chlamydia screening every six months among HIV-infected MSM during regular HIV consultations can
reduce the incidence of both infections among MSM: after 10 years, the relative percentage reduction in chlamydia
incidence would be 15% and in HIV incidence 4%, compared to the current situation. Chlamydia screening is more
effective in reducing HIV incidence with more frequent screening and with higher participation of the most risky
MSM in the screening program.
Conclusions: Chlamydia infection could contribute to the transmission of HIV among MSM. Preventive measures
reducing chlamydia prevalence, such as routine chlamydia screening of HIV-infected MSM, can result in a decline in
the incidence of chlamydia and HIV.
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In several countries, high prevalences of asymptomatic
rectal chlamydia have been found among HIV-infected
men who have sex with men (MSM) [1-4]. Most of these
infections remain undetected and untreated. Therefore,
screening for chlamydia among HIV-infected MSM may
considerably reduce the prevalence of chlamydia in this* Correspondence: maria.xiridou@rivm.nl
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reproduction in any medium, provided the orspecific subpopulation. In addition, certain studies suggest
that chlamydia screening among MSM may result in a de-
cline in HIV transmission, because infection with chla-
mydia may increase the transmissibility of HIV (for
HIV-infected individuals) and the susceptibility to HIV
infection (for HIV-negative individuals) [5-11]. However,
the benefits of chlamydia screening are still unclear; for
MSM, this is because of the perceived mildness of compli-
cations of chlamydia infection in men.
In this study, we investigated the role of rectal chla-
mydia in the spread of HIV among MSM, using a dynamic
transmission model. An increase in HIV infectivity andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the model. Also, we accounted for the impact of anti-
retroviral therapy (ART) in reducing HIV infectivity and
in eliminating the increase in HIV infectivity due to co-
infection with chlamydia. We examined how chlamydia
affects the spread of HIV in the population, by calculating
the fraction of new HIV infections attributable to chla-
mydia infection. Subsequently, we studied the impact of
chlamydia screening among HIV-infected MSM at HIV
treatment centres on the incidence of chlamydia and HIV
in the MSM population. To reveal the dependence of the
results on the assumption of increased HIV infectivity and
susceptibility due to chlamydia, the results were calculated
with different levels of this increase.
Methods
The model
We developed a deterministic compartmental model
that describes the transmission of HIV and chlamydia
among sexually active MSM. In the model, infection
with HIV or with chlamydia occurs only via unprotected
anal intercourse (UAI) between men. Three types of
partnerships are distinguished in the model: steady part-
ners, single-act casual partners (with whom they have
only one sexual contact and that is UAI), and multiple-
acts casual partners (with whom they have multiple sexual
contacts of which at least one is UAI). The population is
stratified into four sexual risk groups, with increasing
level of sexual risk behaviour: low, fairly high, very
high, and extremely high (the last three are referred to
as high risk groups). The level of risk behaviour is de-
termined by the total number of sexual partners with
whom men have UAI. Low risk MSM have no UAI
with casual partners. High risk MSM have UAI with
casual partners; the total number of partners is highest
in the extremely high risk group and lowest in the
fairly high risk group (Additional file 1: Table S2).
The population is also stratified according to state of
HIV infection and state of chlamydia infection. Three
states of HIV infection are distinguished in the model:
not infected with HIV, HIV-infected not in care, and
HIV-infected in care (Figure 1). HIV-infected MSM not
in care are unaware of their infection or they are aware
of their infection but have not (yet) been registered at a
specialised HIV treatment centre. HIV-infected MSM in
care are aware of their infection and have been regis-
tered at a specialised HIV treatment centre; they re-
ceive regular clinical care and initiate antiretroviral
therapy (ART) guided by their CD4 counts. Most of
the HIV-infected men in care receive ART [12]; hence,
in the model, HIV infectivity for those in care is lower
than HIV infectivity for those not in care, due to ART.
For chlamydia infection, three states are distinguished:
susceptible to chlamydia, symptomatic chlamydia, andasymptomatic chlamydia (Figure 1). The duration of
symptomatic chlamydia is generally much shorter than
that for asymptomatic chlamydia due to care seeking
behaviour and treatment. Those without symptoms
usually remain undetected until natural recovery; with
screening, they may be detected and treated and be-
come susceptible (see details below for chlamydia
screening).
The model is defined by a system of differential
equations and the parameters are defined in Additional
file 1: Tables S1–S3. The model was parameterized and
calibrated to reflect the current situation among MSM
in the Netherlands (see section about the uncertainty
analysis).
Increased HIV infectivity and susceptibility due to
chlamydia infection
We assumed that for individuals infected with both HIV
and chlamydia, the level of HIV infectivity is increased
by a factor v (compared to HIV infectivity for individuals
without chlamydia), due to co-infection with chlamydia
[7-9]. For those infected with chlamydia but not HIV,
the susceptibility to HIV infection is increased by a fac-
tor φ (compared to HIV susceptibility for those without
chlamydia), due to chlamydia infection [10,11]. The
number of new HIV infections that can be attributed to
infection with chlamydia was calculated as the difference
between the total number of new HIV infections and the
number of new HIV infections if the two factors were
both equal to one. Dividing this number by the total num-
ber of new HIV infections resulted in the fraction of new
HIV infections attributable to infection with chlamydia.
Uncertainty analysis and model calibration
To account for uncertainty in model parameters, a range
of possible values was assigned to each uncertain param-
eter. Using Latin Hypercube Sampling [13], 10,000 sets
of values were sampled from the uniform distribution
on these ranges. The model equations were then solved
numerically with each of the 10,000 parameter sets until
the system reached a stable state; this is assumed to rep-
resent the current situation in the Netherlands (results
with the current opportunistic screening rates for chla-
mydia – see details on screening scenarios below).
Then we calibrated the model to the current number
of HIV-infected MSM in care at HIV treatment centres
in the Netherlands (N = 8,523 in 2011 [14]). Let Zi de-
note the number of HIV-infected MSM in care calcu-
lated from the model with the i-th set of parameter
values, for i = 1,2,…,10,000. We calculated the Poisson
likelihood of each estimate Zi by assuming that the num-
ber of HIV-infected MSM in care follows the Poisson
distribution with mean Zi. This likelihood represents the
probability of observing the value 8,523, if the true
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Figure 1 Flow diagram of the model describing transmission of HIV and chlamydia. The population consists only of men who have sex
with men (MSM). The solid black arrows show infection with chlamydia and the solid red arrows show infection with HIV. HIV-infected MSM not
in care may “enter care” and move to the class of HIV-infected MSM in care (dashed red arrows) after a positive HIV-test and registration at one
of the specialised HIV treatment centres. Recovery from chlamydia infection (with or without treatment) is shown with dashed black arrows. For
the variables Xij the first subscript denotes status of HIV infection (0, not infected with HIV; 1, HIV-infected not in care; 2, HIV-infected in care),
while the second subscript denotes status of chlamydia infection (0, no chlamydia infection; 1, symptomatic chlamydia; 2, asymptomatic
chlamydia). The yellow shaded area denotes MSM not infected with HIV, the blue shaded area denotes HIV-infected MSM not in care, and the
pink shaded area denotes HIV-infected MSM in care.
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mates Zi is assigned a likelihood representing how likely
this estimate is, given our current knowledge. Subse-
quently, we selected the parameter sets with high likeli-
hood: those with likelihood higher than 1/8 of the
saturated likelihood (which is the likelihood of the value
8,523 from the Poisson distribution with mean 8,523):
0.0043212/8 = 0.00054. In this way, we selected the par-
ameter combinations resulting in likely estimates of the
number of HIV-infected MSM in care and excluded
those resulting in unlikely estimates. In the remaining of
the manuscript, we present results only from the se-
lected parameter sets.
Next, the screening rates were modified to reflect
changes in the testing frequency of MSM. The model
equations were solved with the new screening rates and
the selected parameter sets for the subsequent thirtyyears. For each outcome of interest (for example, preva-
lence of HIV) we report the median and the interquartile
range (IQR: from the 25th to the 75th value) of the values
calculated only with the selected parameters.
Scenarios for chlamydia screening
Current opportunistic chlamydia screening
Currently in the Netherlands, there is no routine screen-
ing for chlamydia, but only opportunistic screening: indi-
viduals without chlamydia symptoms may be tested for
chlamydia and other sexually transmitted infections (STIs)
at their own initiative, at STI clinics or general practi-
tioners. The current frequency of opportunistic screening
was estimated as follows: low risk men are tested every
2.5-3.5 years; high risk men in care every 1–1.5 years; high
risk men not infected with HIV or HIV-infected not in
care every 1.5-2.5 years [1,15] (Additional file 1: Table S3).
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screening among MSM
To reveal the impact of the current opportunistic chla-
mydia screening on the incidence of chlamydia and HIV,
we examined first a hypothetical scenario where the fre-
quency of opportunistic screening is reduced. This could
happen, for instance, if campaigns promoting chlamydia
screening are relaxed or if the need to treat asymptom-
atic chlamydia is perceived as less important than it is
now. This scenario was implemented by increasing the
time interval between chlamydia tests by 50%: low risk
men are tested every 3.75-5.25 years; high risk men in
care every 1.5-2.25 years; high risk men who are not
infected with HIV or HIV-infected not in care every
2.25-3.75 years.
Introduction of routine chlamydia screening of HIV-infected
MSM in care at HIV treatment centres
Chlamydia screening among HIV-infected MSM in care
could have an impact on reducing HIV transmission, be-
cause chlamydia infection may increase HIV infectivity.
Moreover, chlamydia screening could be implemented
during the existing visits of HIV-infected men at HIV
treatment centres. To investigate the impact of such a
program, we examined three hypothetical scenarios with
different screening frequencies: every twelve months,
every six months, or every four months. In these scenar-
ios, it is assumed that: only HIV-infected MSM in care
are screened; routine screening is added to (and not re-
placing) the current opportunistic screening; participa-
tion in the routine screening program is 100%, which
means that all HIV-infected MSM in care are screened
(and treated if positive) every twelve, six, or four months.
The three scenarios are referred to as routine screening at
HIV treatment centres; we present its impact on reducing
HIV incidence in the whole MSM population.
Suboptimal participation in routine chlamydia screening of
HIV-infected MSM in care at HIV treatment centres
Although HIV-infected MSM in care have regular con-
sultations at HIV treatment centres, some of them may
not participate in the routine screening program (for in-
stance, because they have been recently tested at STI
clinics, due to symptoms or known risk of exposure) or
they may participate but not return to receive their
medication, if they are found positive (mostly because of
the lack of symptoms or hindrance [16]). In addition, re-
cent data suggest that the current treatment may not be
100% effective [17]. To model these conditions, we
recalculated the impact of one of the scenarios for rou-
tine screening assuming that participation is suboptimal
(less than 100%); this was done for the scenario with
screening every six months, also referred to as semi-
annual screening. In order to examine the role of thedifferent sexual risk groups, we studied four scenarios:
in each scenario, participation was 80% in one of the
four sexual risk groups and 100% in the other three risk
groups:
– 80% participation of low risk HIV-infected MSM in
care;
– 80% participation of fairly high risk HIV-infected
MSM in care;
– 80% participation of very high risk HIV-infected
MSM in care;
– 80% participation of extremely high risk HIV-
infected MSM in care.
Percentage change in incidence
For the above mentioned screening scenarios, we show
the percentage change in HIV incidence and the per-
centage change in chlamydia incidence, calculated as
100
current − newð Þ
current
where, “current” is the incidence with the current oppor-
tunistic screening and “new” is the incidence with the
new screening scenario.
Results
The interaction between HIV and chlamydia
First, we calculated from the model the prevalence and
the incidence of HIV and of chlamydia infection, for the
current situation in the Netherlands (with only oppor-
tunistic screening). The calculated median prevalence of
HIV is 4.26% (IQR, 4.19-4.33%) and the median preva-
lence of chlamydia 2.69% (IQR, 1.68-3.71%) in the MSM
population. However, large variations are observed in
the prevalences of HIV and chlamydia within the popu-
lation. Specifically, the prevalence of HIV varies from
0.5% in the lowest risk group to 72.8% in the highest risk
group; the prevalence of chlamydia infections varies
from 0.1% in the lowest risk group to 57.6% in the
highest risk group (Additional file 1: Figure S1).
The median prevalence of chlamydia is 1.8% among
MSM not infected with HIV, but 22.7% among HIV-
infected MSM (Additional file 1: Figure S2). The high
prevalence of chlamydia among HIV-infected MSM is
mostly attributable to the high risk behaviour in this
specific subgroup. From the model, it was calculated that
MSM who have UAI with casual partners (high risk
MSM) comprise 90.8% of the HIV-infected MSM popu-
lation, but only 24.5% of the MSM not infected with
HIV. This implies that the men who get infected with
HIV are mostly those with high sexual risk behaviour
(having UAI with casual partners) and because of their
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infected with chlamydia.
Among all new HIV infections, 15.2% (IQR, 8.9-19.8%)
can be attributed to infection with chlamydia, specific-
ally to the increased HIV infectivity and increased HIV
susceptibility in those infected with chlamydia. This per-
centage is higher if the factors increasing HIV infectivity
and HIV susceptibility due to chlamydia are higher,
since, per definition, these factors determine the extra
HIV infections attributable to chlamydia (Figure 2a,b).
The percentage of HIV infections attributable to infec-
tion with chlamydia is also higher if chlamydia infectivity
is higher, because chlamydia incidence is then higher
and that intensifies the interaction with HIV; however,
the percentage is lower if HIV infectivity is higher, since
then the dynamics of HIV transmission are quite strong
and can hardly be affected by chlamydia (Figure 2c,d).(a)
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Figure 2 The percentage of new HIV infections that can be attributed
uncertain parameters: (a) the factor increase in susceptibility to HIV due to
with chlamydia; (c) the probability of chlamydia transmission per act of un
per UAI act. In each plot, one point corresponds to one of the selected par
viewed on the horizontal axis, while the percentage of new HIV infections
parameter value) is shown on the vertical axis.The impact of chlamydia screening on the incidence of
HIV and of chlamydia
If MSM are less frequently tested for chlamydia, the in-
cidence of both chlamydia and HIV may increase. In
particular, increasing the screening period for chlamydia
by 50% may lead to an increase of 6% in chlamydia inci-
dence and 2% in HIV incidence among MSM (Figure 3
and Additional file 1: Figures S3-S4).
The introduction of routine chlamydia screening of
HIV-infected MSM in care can result in considerable re-
ductions in the incidence of chlamydia, as well as of
HIV (Figure 4). Ten years after the introduction of rou-
tine screening, the incidence of HIV among MSM is re-
duced by 2%, 4%, or 5% if routine screening is carried
out every twelve, six, or four months, respectively; chla-
mydia incidence is reduced by 7%, 15%, or 22% if routine
screening is carried out every twelve, six, or four months,(b)
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Figure 3 Change in HIV and chlamydia incidence, after a reduction in the frequency of chlamydia screening. Percentage change in the
incidence of HIV (blue) and chlamydia (red) among MSM, after a reduction in the frequency of opportunistic chlamydia screening (the time
interval between chlamydia tests as currently reported by MSM is increased by 50%). The percentage change is calculated compared to the
current situation, with only opportunistic chlamydia screening (see Methods and Additional file 1: Table S3). In each year, the lines represent the
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fective in reducing HIV incidence when the frequency of
UAI with multiple-acts casual partners is low (Figure 4b
and Additional file 1: Figure S5). This can be explained by
the fact that with low UAI frequency the dynamics of HIV
transmission are rather weak and that makes the impact
of screening more prominent, while, with high UAI fre-
quency, the dynamics of HIV transmission are too strong
and can hardly be affected by chlamydia screening. Chla-
mydia screening is more effective in reducing HIV inci-
dence also when the factors enhancing HIV infectivity and
HIV susceptibility are high (Figure 4c,d and Additional
file 1: Figure S5), because then the contribution of chla-
mydia to HIV transmission is higher, as shown in the
previous paragraph.
The impact of screening as shown in Figure 4 will
however be lower, if participation in routine chlamydia
screening of HIV-infected MSM in care is suboptimal.
The importance of sexual risk behaviour should be em-
phasized here. Figure 5 shows the percentage decline in
HIV and chlamydia incidence with 100% participation in
the routine screening program and with 80% participa-
tion in one of the four sexual risk groups. The impact of
chlamydia screening is smaller if participation is subopti-
mal in the group with the highest risk behaviour, com-
pared to the impact of screening if participation is
suboptimal in the group with the lowest risk behaviour.
Discussion
In this modelling study, we showed that routine chla-
mydia screening among HIV-infected MSM in care can
result in reductions in chlamydia and HIV incidence in
the overall MSM population. The impact of chlamydia
screening on HIV incidence is a result of the increasedHIV infectivity and susceptibility in individuals infected
with chlamydia. The impact of chlamydia screening specif-
ically among HIV-infected MSM in care can be explained
by the fact that chlamydia incidence among HIV-infected
MSM in care is much higher than among other MSM, due
to the high density of high risk MSM within the HIV-
infected population. Therefore, reducing chlamydia trans-
mission in this core group will result in health gains not
only for themselves, but also for the rest of the MSM popu-
lation by preventing new chlamydia and HIV infections.
It should be stressed that the impact of chlamydia on
HIV transmission shown here depends on the assump-
tion of increased HIV infectivity and susceptibility due
to chlamydia infection. This impact declines as the in-
crease in HIV infectivity and susceptibility becomes
smaller (Figures 2a,b and 4c,d); and if HIV infectivity
and susceptibility are not altered at all in those with
chlamydia infection, then chlamydia has no effect on
HIV transmission. On the other hand, the decline in
HIV incidence that we found due to chlamydia screening
of HIV-infected MSM in care is not very high, as is the
case with other interventions, such as widespread use of
ART [18-20], or as previous studies have suggested [5,6].
This is a result of two factors. First, we assumed that
HIV infectivity and HIV susceptibility are increased due
to chlamydia infection by a factor of two, at most. Other
modelling studies for heterosexuals have assumed higher
increases [5,19], but we found no studies with significant
evidence of such high increases [7-11]. Second, the in-
crease in HIV infectivity due to chlamydia is diminished
in individuals with undetectable viral load [9,21]; these
individuals comprise the majority of the target group,
since most of the HIV-infected MSM in care receive
ART and most of them have undetectable viral load [14].
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Figure 4 Change in HIV and chlamydia incidence, due to routine chlamydia screening among HIV-infected MSM in-care. Percentage
change in the incidence of HIV or chlamydia among MSM, ten years after the introduction of routine chlamydia screening among HIV-infected
MSM in care. The percentage change is calculated compared to the current situation, with only opportunistic chlamydia screening.
(a) Percentage change in HIV (blue) and chlamydia (red) incidence, with routine chlamydia screening carried out every twelve, six, or four months.
The boxes represent the interquartile range of the results; the white segment within the box represents the median of the results; the line
segments above and below the boxes show the whole range of the results. (b-d) The percentage change in HIV incidence due to routine
chlamydia screening of HIV-infected MSM in care every six months, plotted against three of the uncertain parameters: the number of acts of
unprotected anal intercourse (UAI) per year per multiple-acts casual partner; the factor increase in susceptibility to HIV due to chlamydia; the factor
increase in HIV infectivity due to co-infection with chlamydia.
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erosexuals has been investigated in several modelling
studies (see, for instance, [6,22-26]). For MSM popula-
tions, this is the first study that addresses this issue and
examines the impact of chlamydia screening specifically
among HIV-infected MSM registered at HIV treatment
centres. This is a high risk population, contributing the
most to HIV and chlamydia transmission. Moreover,
screening HIV-infected MSM in care can be easily
implemented during the regular visits of these men at
HIV clinics.
Certain limitations of this study should be mentioned.
A test for anogenital chlamydia, in practice, may be car-
ried out in combination with a test for gonorrhoea.
Therefore, gonorrhoea infections may also be detectedand treated, resulting in extra reduction in HIV trans-
mission, since gonorrhoea also increases HIV infectivity
and susceptibility [7,11]. From this point, our model
may have underestimated the impact of routine chla-
mydia screening, as it does not account for the indirect
effect of combined screening for chlamydia and gonor-
rhoea. Furthermore, some individuals treated for gonor-
rhoea, may also receive treatment for chlamydia; in that
case the prevalence of chlamydia is reduced and conse-
quently the impact of chlamydia screening could be
lower.
Studies among individuals with recently acquired HIV
infection have found high prevalences of chlamydia,
suggesting that co-transmission of HIV and chlamydia
could be possible and even frequent [27-29]. However,
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Figure 5 The impact of suboptimal participation in routine chlamydia screening. The percentage change in HIV incidence (blue) and
chlamydia incidence (red), ten years after the introduction of routine chlamydia screening among HIV-infected MSM in care with suboptimal
participation in the screening program: participation is 80% in only one of the four sexual risk groups and 100% in the other three risk groups.
The four risk groups are: low risk, fairly high risk, very high risk, and extremely high risk, with increasing number of sexual partners. The results for
the case with 100% participation of all HIV-infected MSM in care (first columns in both plots) are shown for comparison. The height of the
columns shows the median and the line segments show the interquartile range of the results with the selected parameter sets.
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acquired via the same sexual contact or to inform parame-
ters relating to co-transmission. Therefore transmission of
HIV and of chlamydia was modelled separately, such that
co-transmission of the two infections is not possible and
hence its potential impact is not accounted for in the
model. Moreover, we did not account for orogenital trans-
mission of HIV and chlamydia due to the lack of data. To
avoid bias, we consistently restricted all related parameters
and data to anogenital transmission, as much as possible.
Nevertheless, for some parameters, data on heterosexual
transmission were used, since there were no data for
transmission between MSM.
Earlier modelling studies have shown that a substantial
proportion of new HIV infections can be attributed to
individuals with acute HIV infection [30,31], due to the
high level of HIV infectivity during this short stage. This
means that the impact of chlamydia might be overestimated
in this study, since the impact is reduced with higher HIV
infectivity (Figure 2d). Due to the complexity of the model,acute HIV infection was not included. Moreover, we did not
account for differences in the duration of asymptomatic
chlamydia between HIV-infected and HIV-negative MSM,
because there are hardly any data on asymptomatic infec-
tions. Finally, in our calculations, we assumed a moderately
assortative pattern of sexual mixing [32,33]; the role of
mixing on the spread of STIs has been investigated in previ-
ous modelling studies (see, for instance, [34-37]).
After the introduction of routine chlamydia screening at
HIV treatment centres, HIV-infected MSM in care may
be less likely to be tested opportunistically outside the
routine screening program. This means that HIV-infected
MSM in care may not seek STI testing after symptoms or
known risk of exposure, awaiting for the arranged regular
visit at the HIV treatment centre. Moreover, opportunistic
STI screening is mostly implemented at STI clinics, where
also safe sex counselling and partner notification are of-
fered. This means that introduction of routine chlamydia
screening at HIV treatment centres may result in a reduc-
tion in opportunistic testing for other STIs, a reduction in
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http://www.biomedcentral.com/1471-2334/13/436partner notification, and, consequently, in increases in
transmission of HIV and chlamydia. From this point, it is
important that HIV-infected MSM in care who test posi-
tive for chlamydia during routine screening will still be of-
fered a full STI consultation including safe sex counselling
and partner notification.
These results have important implications for the de-
sign of public health policy interventions. Measures that
can reduce chlamydia prevalence, such as chlamydia
screening among HIV-infected MSM in care, should be
promoted because they may also contribute to reducing
HIV transmission. However, they should be considered
as an addition to (and not as a substitute of ) other mea-
sures to control HIV. Furthermore, it is essential that in
particular high risk MSM participate in screening pro-
grams. Finally, it should be stressed that although data
from the Netherlands were used for population charac-
teristics in our model, such as sexual risk behaviour, our
results were robust to changes in these characteristics.
Hence, our findings apply also to other countries with
considerable HIV and STI transmission among MSM.Conclusions
In conclusion, this analysis shows that chlamydia infection
could have a considerable contribution to the population
spread of HIV among MSM. Routine chlamydia screening
of HIV-infected MSM at HIV treatment centres has the
potential to reduce HIV and chlamydia incidence not only
in the screened population of HIV-infected MSM in care,
but among all MSM. Chlamydia screening will be more ef-
fective in reducing HIV incidence with more frequent
testing or with higher participation of high-risk MSM in
the screening program.Additional file
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